Emrich, I. E. http://orcid.org/0000-0002-5048-3659
Lizzi, F.
Siegel, J. D.
Seiler-Mussler, S.
Ukena, C.
Kaddu-Mulindwa, D.
D’Amelio, R.
Wagenpfeil, S.
Brandenburg, V. M.
Böhm, M.
Fliser, D.
Heine, G. H.
Funding for this research was provided by:
Pharmacosmos Holbaek Danemark
Article History
Received: 22 February 2020
Accepted: 19 May 2020
First Online: 13 July 2020
Ethics approval and consent to participate
: All participants gave their written informed consent at baseline. The study was carried out in accordance with the Declaration of Helsinki and approved by the local Ethics Committee (Ehtikkommission der Ärztekammer des Saarlandes, Saarbrücken, Germany).
: All participants gave their written informed consent at baseline for performing the trial and for presenting/publishing the results.
: Dr. Emrich received advisory board and speaker honoraria from Pharmacosmos. Dr. Heine and Dr. Brandenburg received advisory board and speaker honoraria from Pharmacosmos and from Vifor. Dr. Böhm is supported by the Deutsche Forschungsgemeinschaft (DFG, TTR 219, S-01, M-03, M-05) and reports support from Abbott, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Medtronic, Novartis, ReCor, Servier, and Vifor. Dr. Wagenpfeil is supported by the Deutsche Forschungsgemeinschaft (DGF, TTR 219, PI: S-01) and reports support from Servier. Dr. Fliser is supported by the Deutsche Forschungsgemeinschaft (DGF, TTR 219) and reports support from Abbott, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, FMC, Medtronic, Novartis, ReCor, Servier, and Vifor. Dr. Kaddu-Mulindwa reports support from Gilead, Janssen-Cilag, BMS, Takeda, Roche, Novartis, Hexal, and Viiv.Fabio Lizzi, Jonathan Siegel, Sarah Seiler-Mußler, Christian Ukena, and Roberto D’Amelio have no conflict of interests.